UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000028075
Receipt number R000031711
Scientific Title A phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and phase I study of this drug for recurrent or refractory neuroblastoma
Date of disclosure of the study information 2017/07/19
Last modified on 2022/07/11 08:36:03

No. Disposal Last modified on Item of update
1 Insert 2017/07/05 09:32:14
2 Update 2017/07/14 11:43:40 Primary outcomes
Key secondary outcomes
Key secondary outcomes
3 Update 2017/07/14 12:23:03 Interventions/Control_1
Interventions/Control_1
Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
4 Update 2017/07/14 13:05:06 Date of protocol fixation
5 Update 2017/07/18 17:40:22 Condition
Narrative objectives1
6 Update 2017/07/18 17:43:16 Key inclusion criteria
7 Update 2017/07/18 17:43:49 Key inclusion criteria
8 Update 2017/07/25 09:43:18 UMIN ID1
UMIN ID2
UMIN ID3
9 Update 2017/08/21 13:28:58 Research ethics review
10 Update 2017/10/18 19:17:31 Recruitment status
11 Update 2018/11/19 09:03:09 Recruitment status
12 Update 2019/01/07 08:53:34 Recruitment status
Publication of results
13 Update 2019/03/25 09:48:29 Recruitment status
Date of IRB
Other related information
14 Update 2019/03/25 09:49:01 Publication of results
15 Update 2019/03/25 09:53:16 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
16 Update 2020/11/20 16:22:47 Other related information
17 Update 2021/07/07 09:34:52 Other related information
18 Update 2022/07/11 08:36:03 Recruitment status
Last follow-up date
Date analysis concluded
Other related information